Novel mutations of HSD17B3 in three Chinese patients with 46,XY Disorders of Sex Development

• Published in: Steroids 2017-10, Vol.126, p.1-6
• Main Authors: Yu, Bingqing, Liu, Zhaoxiang, Mao, Jiangfeng, Wang, Xi, Zheng, Junjie, Xiong, Shuyu, Cui, Mingxuan, Ma, Wanlu, Huang, Qibin, Xu, Hongli, Huang, Bingkun, Nie, Min, Wu, Xueyan
• Format: Article
• Language: English
• Subjects: 17-Hydroxysteroid Dehydrogenases - genetics; 17β-Hydroxysteroid dehydrogenase type 3 deficiency; 46, XY Disorders of Sex Development - genetics; 46,XY Disorders of Sex Development; Adult; Asian Continental Ancestry Group - genetics; Child; Child, Preschool; Female; Homozygote; HSD17B3 gene mutations; Humans; Male; Mutation; Phenotype
• ISSN: 0039-128X; 1878-5867
• DOI: 10.1016/j.steroids.2017.07.009

•Three novel HSD17B3 mutations were identified.•“Apparent homozygosity” occurred in a patient with non-consanguineous parents.•Intragenic deletion happened in a patient with monoallelic mutation. 17β-Hydroxysteroid dehydrogenase type 3 (17β-HSD3) converts the inactive Δ4-androstenedione (A) to testosterone (T). Its deficiency is the most common testosterone biosynthesis defect that results in 46,XY Disorders Of Sex Development (DSD). However, the disease is difficult to distinguish from other 46,XY DSD for similar clinical phenotypes. Therefore, genetic testing provides good criteria for the diagnosis of the disease. In this study, HSD17B3 gene was examined in 3 unrelated Chinese patients with 46,XY DSD. Direct sequencing and quantitative PCR of HSD17B3 gene revealed the presence of a compound heterozygous mutation (p.I60T/exon1 deletion) in Patient 1, a homozygous (p.I60T) mutation in Patient 2 and a frameshift mutation (p.V25Efs∗54) and an exon1 deletion in Patient 3. All of the mutations have not been reported previously. These novel mutations may expand the mutation database of HSD17B3 gene and provide us new insights into the molecular mechanism of 17β-HSD3 deficiency. It is noteworthy that when direct sequence analysis showed a rare homozygous mutation in patients with non-consanguineous parents, “apparent homozygosity” should be taken into an account and the intragenic deletion should be screened. In addition, when single mutation was found in patients with disease in recessive heredity mode, the intragenic deletion should also be screened.